A partial agonist for PPARγ (Ki = 160 nM) which induces adipogenesis significantly less than the full activator rosiglitazone; reverses high fat diet-mediated impairments in insulin signaling; does not induce weight gain, hyperphagia, or edema; does not activate PPARα, PPARβ/δ, or RXRα.